What Does Myriad Genetics ($MYGN) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters at a Glance
Myriad Genetics (MYGN) is a US precision diagnostics company focused on hereditary cancer testing and molecular diagnostics. Revenue streams from oncology, prenatal, and mental health tests, the expansion of its new molecular residual disease business, and the reimbursement environment are the key variables driving earnings and the share price.
Subscribe🏢 What kind of company is Myriad Genetics?
Myriad Genetics (MYGN) is a molecular diagnostics company headquartered in the United States. Since its founding, it has built a leading position in gene-based testing for assessing hereditary cancer risk and is regarded as an early pioneer in hereditary cancer testing.
It provides molecular diagnostics services, including the MyRisk hereditary cancer risk test, oncology precision testing, prenatal genetic testing, and the GeneSight mental health pharmacogenomic test. It holds a global leading position in the hereditary cancer testing segment.
💰 How does Myriad Genetics make money?
| Business Segment | Revenue Share | Description | ||||||
|---|---|---|---|---|---|---|---|---|
| Oncology & Hereditary Cancer Testing | Core | MyRisk hereditary cancer risk test and oncology precision testing | ||||||
| Women's Health & Prenatal Testing | Key Growth Driver | Prenatal genetic testing and women's health diagnostics | ||||||
| Mental Health Testing | Diversification Pillar | GeneSight pharmacogenomic test |
1-Year Price Performance
52-Week Price Range
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 GH | Guardant Health Inc | $159.03 | -2.3% | $21.3B | - | - | - | - |
| NTRA | Natera Inc | $326.14 | -1.3% | $47.0B | - | 25.7 | -12.54% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| ILMN | Illumina Inc | $201.27 | -1.8% | $30.4B | 37.5 | 10.7 | 32.38% | - |
| TMO | Thermo Fisher Scientific Inc | $603.18 | -0.4% | $223.0B | 32.5 | 4.2 | 13.51% | 0.31% |
 LH | Labcorp Holdings Inc | $306.96 | -4.4% | $24.9B | 25.4 | 2.9 | 11.74% | 0.96% |
✅ Myriad Genetics investor checkpoints
Key points to check when investing in Myriad Genetics. Trends in hereditary cancer test volumes, the reimbursement environment, and the pace of commercialization of the new molecular residual disease business are the key short- and medium-term variables, and the progress of test category diversification should also be monitored.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🔬 Test Volume Trends | Growth trends in hereditary cancer and prenatal test volumes | Test volumes trending higher |
| 💵 Reimbursement | Coverage and pricing environment for diagnostic tests | Needs monitoring |
| 🧪 New Business Progress | Commercialization progress of molecular residual disease and therapy selection tests | Early expansion phase |
| 📉 Profitability | Test mix and margin trends | Fluctuations need observation |
Reimbursement volatility and intensifying competition in the molecular diagnostics market are short-term risks. If revenue contribution from the new molecular residual disease business is delayed beyond expectations, growth expectations may be revised down, and pricing pressure on tests is also a source of margin volatility.
Myriad Genetics is a precision diagnostics specialist with a first-mover position in hereditary cancer testing and a molecular diagnostics portfolio. The reimbursement environment and the pace of commercialization of the new molecular residual disease business are the key variables to watch, and given the volatile nature of the business, dollar-cost averaging and a long-term perspective are recommended.
Subscribe
Today's 5 AI picks, all free